Saturday, July 19, 2025 7/19/2025

Improved Detection of Prostate Cancer with Nanoparticle-based Ultrasound Contrast Agents Targeted to PSMA

Award Number: R01EB025741
ORGANIZATION: NATIONAL INSTITUTE Of BIOMEDICAL IMAGING & BIOENGINEERING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/15/2017
PERIOD OF PERFORMANCE END DATE: 01/31/2028

Group Awards By:

View Award Description

Improved Detection of Prostate Cancer with Nanoparticle-based Ultrasound Contrast Agents Targeted to PSMA - PROJECT SUMMARY This competitive renewal application focuses on continued development of cancer cell-specific nanobubble (NB) ultrasound contrast agents for real-time guidance of prostate biopsies using transrectal ultrasound (TRUS). In the current clinical workflow, prostate cancer (PCa) biopsies are almost always performed using TRUS guidance. However due to poor soft tissue contrast of the B-mode ultrasound scans, the delineation of tumors within the prostate using TRUS is not clear. Because only 1% of the prostate tissue is sampled with a typical 8-12 core biopsy, a lack of direct guidance of the biopsy to suspicious lesions has led to high false negative rates and rising morbidity from current standard of care. The development of a new tool to accurately depict cancer within the prostate in real-time using TRUS is thus urgently needed to aid in biopsy guidance. To provide a practical tool for clear identification of potential malignancies during prostate biopsies, we have developed a nanoparticle-based ultrasound contrast agent (called a nanobubble) targeted to the prostate specific membrane antigen (PSMA) which is significantly over-expressed in most prostate cancers. The PSMA-NBs, are similar in structure to clinically used microbubbles (MB) and are clearly visible on clinical US. In contrast to MB, which remain in the vasculature, the small size, deformable shell and gas core, enable NBs extravasate and directly bind to cancer cells. This results in highly specific accumulation of contrast at the tumor itself leading to better resolution and detection of PCa. During our initial award, we developed an entirely new platform NB formulation which has been rigorously vetted and tested extensively in animal models of PCa. The objective of the next phase of research proposed in this renewal is to continue working toward clinical translation by performing IND-enabling studies. Here, we will scale up the NB formulation, test batch-to-batch reproducibility, conduct toxicology studies and engineer viable long-term storage techniques. Concurrently we will develop multiparametric US imaging biomarkers unique to NBs and acquisition pulse sequences optimized for use with the NBs to further enhance the sensitivity and specificity of the PSMA-NB technology; there are currently no NB specific image acquisition or processing tools for contrast enhanced ultrasound. We will then test the sensitivity and specificity of PSMA-NB enabled TRUS biopsies in a large animal model of prostate cancer in dogs, which can accommodate clinical TRUS transducers and a near-identical workflow to clinical standard of care. These steps are critical to the advancement of the proposed imaging techniques to clinical use. The proposed research feasibility is supported by strong preliminary data generated by an integrated research team with complementary expertise in NB formulation and PSMA (Exner, Basilion), bubble-US interactions (Kolios), image processing (Wilson), and clinical prostate imaging (Bittencourt). The project outcomes will benefit diagnosis, biopsy, and care of prostate cancer using TRUS and complement the existing clinical workflow.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $486,829 )
2025	2025	CASE WESTERN RESERVE UNIVERSITY	10900 EUCLID AVE	CLEVELAND	OH	44106	CUYAHOGA	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	001	6	1/15/2025	NON-COMPETING CONTINUATION	$486,829
2025	2021	CASE WESTERN RESERVE UNIVERSITY	10900 EUCLID AVE	CLEVELAND	OH	44106	CUYAHOGA	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	4	12/19/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $486,829

Issue Date FY: 2024 ( Subtotal = $536,185 )
2024	2024	CASE WESTERN RESERVE UNIVERSITY	10900 EUCLID AVE	CLEVELAND	OH	44106	CUYAHOGA	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	001	5	4/25/2024	COMPETING CONTINUATION	$39,922
2024	2024	CASE WESTERN RESERVE UNIVERSITY	10900 EUCLID AVE	CLEVELAND	OH	44106	CUYAHOGA	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	5	2/8/2024	COMPETING CONTINUATION	$496,263
														Subtotal = $536,185

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2021	CASE WESTERN RESERVE UNIVERSITY	10900 EUCLID AVE	CLEVELAND	OH	44106	CUYAHOGA	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	4	11/30/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $631,743 )
2021	2021	CASE WESTERN RESERVE UNIVERSITY	10900 EUCLID AVE	CLEVELAND	OH	44106	CUYAHOGA	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	001	4	3/17/2021	NON-COMPETING CONTINUATION	$51,571
2021	2021	CASE WESTERN RESERVE UNIVERSITY	10900 EUCLID AVE	CLEVELAND	OH	44106	CUYAHOGA	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	002	4	5/27/2021	NON-COMPETING CONTINUATION	$0
2021	2021	CASE WESTERN RESERVE UNIVERSITY	10900 EUCLID AVE	CLEVELAND	OH	44106	CUYAHOGA	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	4	12/2/2020	NON-COMPETING CONTINUATION	$580,172
														Subtotal = $631,743

Issue Date FY: 2020 ( Subtotal = $696,216 )
2020	2020	CASE WESTERN RESERVE UNIVERSITY	10900 EUCLID AVE	CLEVELAND	OH	44106	CUYAHOGA	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	3	12/6/2019	NON-COMPETING CONTINUATION	$626,594
2020	2020	CASE WESTERN RESERVE UNIVERSITY	10900 EUCLID AVE	CLEVELAND	OH	44106	CUYAHOGA	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	001	3	1/13/2020	NON-COMPETING CONTINUATION	$69,622
														Subtotal = $696,216

Issue Date FY: 2019 ( Subtotal = $571,879 )
2019	2019	CASE WESTERN RESERVE UNIVERSITY	10900 EUCLID AVE	CLEVELAND	OH	44106	CUYAHOGA	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	2	11/9/2018	NON-COMPETING CONTINUATION	$571,879
														Subtotal = $571,879

Issue Date FY: 2018 ( Subtotal = $599,741 )
2018	2018	CASE WESTERN RESERVE UNIVERSITY	10900 EUCLID AVE	CLEVELAND	OH	44106	CUYAHOGA	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	1	12/6/2017	NEW	$599,741
														Subtotal = $599,741

Grand Total All Awards = $3,522,593

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Improved Detection of Prostate Cancer with Nanoparticle-based Ultrasound Contrast Agents Targeted to PSMA

Award Number: R01EB025741

ORGANIZATION: NATIONAL INSTITUTE Of BIOMEDICAL IMAGING & BIOENGINEERING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/15/2017

PERIOD OF PERFORMANCE END DATE: 01/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer